tiprankstipranks
Trending News
More News >
Andlauer Healthcare Group (TSE:AND)
TSX:AND
Advertisement

Andlauer Healthcare Group (AND) AI Stock Analysis

Compare
72 Followers

Top Page

TSE:AND

Andlauer Healthcare Group

(TSX:AND)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - 4o)
Rating:60Neutral
Price Target:
C$56.00
▲(4.69% Upside)
The overall stock score of 60 reflects a balance of solid financial performance and operational efficiency against the backdrop of negative revenue and cash flow growth. Technical indicators suggest mild upward momentum, but valuation metrics indicate the stock may be overvalued. The absence of earnings call insights and corporate events limits additional context.
Positive Factors
Business Model Strength
The company's focus on healthcare logistics provides a stable revenue base, leveraging specialized services that meet stringent regulatory requirements, ensuring long-term demand.
Operational Efficiency
Strong operational efficiency and healthy margins indicate effective management and cost control, supporting sustainable profitability and competitive advantage.
Balance Sheet Health
A manageable debt-to-equity ratio reflects prudent financial management, ensuring financial stability and flexibility to support future growth initiatives.
Negative Factors
Negative Revenue Growth
Declining revenue growth can signal weakening market demand or competitive pressures, potentially impacting long-term business sustainability and market position.
Free Cash Flow Concerns
Negative free cash flow growth may limit the company's ability to reinvest in its operations or pursue strategic opportunities, affecting long-term growth prospects.
Profit Margin Decline
A declining profit margin could indicate rising costs or pricing pressures, which may erode profitability if not addressed, impacting long-term financial health.

Andlauer Healthcare Group (AND) vs. iShares MSCI Canada ETF (EWC)

Andlauer Healthcare Group Business Overview & Revenue Model

Company DescriptionAndlauer Healthcare Group (AND) is a Canadian company that specializes in providing a comprehensive suite of transportation and logistics services tailored to the healthcare sector. The company operates primarily in two segments: Specialized Transportation and Healthcare Logistics. Its core services include temperature-controlled transportation, logistics services, warehousing, and distribution, which ensure the safe and compliant handling of pharmaceuticals, medical devices, and other healthcare products. With a focus on quality and reliability, Andlauer Healthcare Group supports its clients in navigating the complexities of the healthcare supply chain.
How the Company Makes MoneyAndlauer Healthcare Group generates revenue through a diversified model that includes specialized transportation services and healthcare logistics solutions. In the transportation segment, the company earns money by offering temperature-controlled and time-sensitive transportation services for healthcare products. This involves leveraging a fleet of vehicles equipped to handle delicate medical goods, ensuring timely and compliant delivery. In the logistics segment, revenue is derived from providing warehousing, inventory management, and distribution services that cater specifically to the healthcare industry. These offerings are enhanced by strategic partnerships with healthcare providers and manufacturers, enabling Andlauer to integrate seamlessly into clients' supply chains and support their operational needs. The company’s focus on the healthcare sector allows it to capitalize on the growing demand for specialized logistics solutions, driven by increasing regulatory requirements and the expansion of healthcare services.

Andlauer Healthcare Group Earnings Call Summary

Earnings Call Date:Jul 31, 2025
(Q3-2024)
|
% Change Since: |
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong growth in Canadian operations and improved EBITDA margins, although challenges in the U.S. transportation segment and a decline in packaging revenue persisted. The company remains financially strong and committed to shareholder value initiatives, signaling a cautiously optimistic outlook.
Q3-2024 Updates
Positive Updates
Strong Canadian Transportation Growth
Canadian ground transportation revenue excluding fuel increased by 8.5%, dedicated and last mile was up 10.2%, and air freight forwarding grew by 5.1% compared to Q3 last year.
Improved EBITDA Margin
Consolidated EBITDA margin reached 25.9% for the quarter, up from 24.9% in Q3 last year, marking the strongest quarterly margin in 2024.
Healthcare Logistics Revenue Growth
Healthcare Logistics segment revenue totaled $44.1 million, an increase of 4.7% compared to Q3 last year, with logistics and distribution revenue increasing by 6.7%.
Strong Financial Position
The company maintained a very conservative net leverage ratio of 0.74x with cash and cash equivalents of $36 million and working capital of $47 million at quarter end.
Continued Shareholder Value Initiatives
The company raised its quarterly dividend to $0.11 per share and continued share buyback activities.
Negative Updates
U.S. Transportation Challenges
Continued challenging operating conditions in the U.S. truckload business led to a $1.5 million lower EBITDA in the quarter compared to Q3 last year.
Decline in Packaging Revenue
Packaging revenue declined by 16.7% due to lower volumes.
Lower Contributions from U.S.-based Businesses
Lower contributions from Boyle Transportation and Skelton USA affected overall performance.
Company Guidance
During the Andlauer Healthcare Group's Q3 2024 earnings call, the company provided detailed guidance on its financial performance and strategic focus. The Canadian Grand transportation revenue, excluding fuel, experienced an increase of approximately 8.5% compared to the previous year, while dedicated and last-mile delivery grew by 10.2%, and air freight forwarding rose by 5.1%. The Logistics and Distribution segment saw a 6.8% year-over-year increase in revenue. The consolidated EBITDA margin improved to 25.9%, up from 24.9% in Q3 2023. However, the U.S.-based truckload business faced challenges, with EBITDA attributable to Boyle Transportation and Skelton USA being $1.5 million lower compared to the previous year. Despite these challenges, the company remains focused on improving its specialized U.S. truckload operations and is optimistic about growth opportunities in the Canadian healthcare sector, with plans for organic growth and potential acquisitions. The balance sheet remains strong, with a net leverage ratio of 0.74x and cash and cash equivalents of $36 million.

Andlauer Healthcare Group Financial Statement Overview

Summary
Andlauer Healthcare Group demonstrates strong financial health with consistent revenue growth, robust profitability, and a sound balance sheet. Despite an increase in debt levels, the company efficiently converts income into cash, supporting its operations and growth.
Income Statement
65
Positive
The company has shown consistent revenue growth with the TTM revenue at CAD 655.43 million, up from CAD 650.48 million in the previous year. Gross profit margin remains stable at approximately 22.9% in the TTM. The net profit margin has improved to 10.64% in the TTM, reflecting stronger profitability. EBIT and EBITDA margins are robust at 14.38% and 26.06% respectively, indicating efficient operational management. The overall trajectory is positive with healthy profitability metrics.
Balance Sheet
70
Positive
The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.41 in the TTM, indicating moderate leverage. Return on Equity (ROE) is healthy at 15.72%, showcasing effective utilization of equity. The equity ratio stands at 62.31%, suggesting a strong capital structure with adequate equity to cover liabilities. The company's balance sheet is solid, although the increasing debt levels in the TTM warrant monitoring.
Cash Flow
60
Neutral
The company exhibits strong cash flow generation with TTM operating cash flow of CAD 124.24 million and free cash flow of CAD 105.79 million. Free cash flow growth is modest at 1.7% compared to the previous year, but the operating cash flow to net income ratio is a robust 1.78, indicating excellent cash conversion efficiency. The cash flow position is solid, providing flexibility for future investments or debt repayment.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue655.43M650.48M647.95M648.42M440.12M314.34M
Gross Profit149.89M147.20M147.48M158.85M110.75M79.55M
EBITDA170.76M166.72M166.96M175.07M154.91M79.20M
Net Income69.77M64.47M66.14M76.28M89.95M37.71M
Balance Sheet
Total Assets712.63M696.92M682.43M712.46M644.17M252.80M
Cash, Cash Equivalents and Short-Term Investments44.10M40.48M59.74M65.86M24.99M30.15M
Total Debt182.60M181.21M127.90M163.29M187.25M129.61M
Total Liabilities268.57M265.78M212.86M271.47M292.05M158.47M
Stockholders Equity444.06M431.13M469.57M440.99M352.12M94.33M
Cash Flow
Free Cash Flow105.79M104.02M78.83M109.17M74.42M45.56M
Operating Cash Flow124.24M124.40M104.42M137.13M84.09M51.00M
Investing Cash Flow-24.23M-18.86M-23.85M-45.56M-183.38M-20.37M
Financing Cash Flow-124.86M-126.24M-86.18M-51.59M93.89M-19.20M

Andlauer Healthcare Group Technical Analysis

Technical Analysis Sentiment
Positive
Last Price53.49
Price Trends
50DMA
52.96
Positive
100DMA
52.85
Positive
200DMA
48.75
Positive
Market Momentum
MACD
-0.26
Negative
RSI
60.20
Neutral
STOCH
63.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AND, the sentiment is Positive. The current price of 53.49 is above the 20-day moving average (MA) of 52.52, above the 50-day MA of 52.96, and above the 200-day MA of 48.75, indicating a bullish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 60.20 is Neutral, neither overbought nor oversold. The STOCH value of 63.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AND.

Andlauer Healthcare Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
$1.26B8.8519.73%1.71%14.37%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
60
Neutral
$2.08B30.9415.64%0.88%0.34%10.40%
53
Neutral
C$61.96M-24.17%5.93%2.28%-1613.54%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:AND
Andlauer Healthcare Group
53.49
13.36
33.30%
TSE:TTNM
Titanium Transportation
1.35
-0.91
-40.27%
TSE:CJT
Cargojet
81.64
-51.85
-38.84%

Andlauer Healthcare Group Corporate Events

M&A TransactionsFinancial Disclosures
Andlauer Healthcare Group Reports Q2 2025 Results Amid Acquisition by UPS
Neutral
Jul 31, 2025

Andlauer Healthcare Group reported a decrease in revenue for Q2 2025, primarily due to challenges in its US-based truckload businesses and the deconsolidation of a packaging subsidiary. Despite these challenges, the company maintained its EBITDA margin within the target range. The company is set to be acquired by UPS in an all-cash transaction valued at approximately $2.2 billion, with the transaction expected to close in the second half of the year, pending regulatory approval.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$42.00 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.

M&A TransactionsBusiness Operations and Strategy
Andlauer Healthcare Group’s Acquisition by UPS Affiliate Approved
Positive
Jun 26, 2025

Andlauer Healthcare Group has received a final order from the Ontario Superior Court of Justice approving its acquisition by a UPS affiliate for C$55.00 per share. The transaction is expected to conclude in the latter half of the year, pending approval under the Canadian Competition Act and fulfillment of customary conditions. This acquisition marks a significant development for AHG, potentially enhancing its market presence and operational capabilities within the healthcare supply chain sector.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$42.00 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.

M&A TransactionsShareholder Meetings
Andlauer Healthcare Group Secures Shareholder Approval for UPS Acquisition
Positive
Jun 24, 2025

Andlauer Healthcare Group has received shareholder approval for its acquisition by UPS at a rate of C$55.00 per share, following an overwhelmingly favorable vote at a special meeting. The transaction, which is pending final court approval and regulatory clearances, signifies a strategic move that could enhance AHG’s market positioning and operational capabilities within the healthcare logistics industry.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$45.00 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.

Dividends
Andlauer Healthcare Group Declares Q2 Dividend
Positive
Jun 13, 2025

Andlauer Healthcare Group Inc. has announced a second quarter dividend of $0.12 per share for both subordinate and multiple voting shares, payable on July 15, 2025. This announcement reflects the company’s continued commitment to providing shareholder value and may enhance its attractiveness to investors, reinforcing its position in the healthcare logistics and transportation industry.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$44.50 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.

M&A TransactionsShareholder Meetings
Andlauer Healthcare Group Announces Shareholder Meeting for UPS Acquisition
Neutral
Jun 2, 2025

Andlauer Healthcare Group has announced the availability of its management information circular related to a special meeting where shareholders will vote on a resolution for UPS to acquire all outstanding shares at C$55.00 per share. The acquisition plan has strong support from major shareholders, representing approximately 82.4% of the total voting power. The Ontario Superior Court of Justice has issued an interim order authorizing the meeting, and the final arrangement is subject to court approval and regulatory clearances. A potential Canada Post labor disruption may delay the delivery of meeting materials to some Canadian shareholders, but electronic access is available.

The most recent analyst rating on (TSE:AND) stock is a Hold with a C$42.00 price target. To see the full list of analyst forecasts on Andlauer Healthcare Group stock, see the TSE:AND Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 19, 2025